Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease that affects multiple brain systems. Formerly known as striatonigral degeneration, olivopontocerebellar atrophy, or Shy-Drager syndrome, MSA is now recognized as a single disease entity with two main clinical subtypes: MSA-P (parkinsonian variant) and MSA-C (cerebellar variant)1. The disease is characterized by autonomic failure, parkinsonism, and cerebellar ataxia, with pathologic hallmark being glial cytoplasmic inclusions (GCIs) containing aggregated alpha-synuclein2. [1]
MSA has an estimated prevalence of 3.4-5.0 per 100,000 individuals, with an annual incidence of approximately 0.6 per 100,0003. The disease typically presents in the sixth decade of life, with a mean age of onset between 53-58 years4. There is no clear gender predilection, and most cases are sporadic, though rare familial occurrences have been reported5. [2]
MSA-P (Parkinsonian Variant): This subtype accounts for approximately 60-70% of MSA cases in Western populations. Core features include asymmetric parkinsonism with bradykinesia, rigidity, and postural instability. Tremor is typically less prominent than in Parkinson's disease. Poor levodopa responsiveness is a key diagnostic feature, with less than 30% of patients showing meaningful improvement6. [3]
MSA-C (Cerebellar Variant): More common in Asian populations, this subtype features prominent cerebellar ataxia including gait instability, limb incoordination, scanning speech, and nystagmus. Cerebellar oculomotor abnormalities are frequently observed7. [4]
Autonomic failure is a cardinal feature of MSA and often presents early in the disease course: [5]
REM sleep behavior disorder (RBD) is present in over 80% of MSA patients and often precedes the motor diagnosis by years or decades10. RBD manifests as loss of muscle atonia during REM sleep, leading to violent dream-enacting behaviors. Sleep-disordered breathing, particularly obstructive sleep apnea, is also common11. [6]
The pathognomonic feature of MSA is the glial cytoplasmic inclusion (GCI), first described by Papp and Lantos in 198912. These are argyrophilic, fibrillar inclusions primarily found in oligodendrocytes, the myelin-producing cells of the central nervous system. GCIs contain: [7]
Neurodegeneration in MSA is characterized by: [8]
Oligodendrocyte dysfunction and myelin loss are prominent features. GCIs disrupt oligodendrocyte function, leading to widespread white matter pathology. MRI studies demonstrate signal abnormalities in the putamen, middle cerebellar peduncle, and pontocerebellar pathways20. [9]
The central pathogenic mechanism in MSA is the aggregation of alpha-synuclein into insoluble fibrils. Unlike Parkinson's disease where neuronal Lewy bodies dominate, MSA features predominantly oligodendroglial inclusions: [10]
Complex I deficiency has been documented in MSA brain tissue, with reduced activity in the substantia nigra and putamen24. This mitochondrial dysfunction leads to: [11]
Microglial activation is extensive in MSA brain tissue, with elevated levels of: [12]
Oligodendrocyte-specific genes are downregulated in MSA, including: [13]
This transcriptional dysregulation contributes to myelin instability and vulnerability to alpha-synuclein toxicity. [14]
The striatonigral system is severely affected in MSA-P: [15]
The resulting disruption of basal ganglia output leads to parkinsonian features including bradykinesia, rigidity, and postural instability. [16]
In MSA-C, the olivopontocerebellar system is primarily affected: [17]
This circuitry disruption underlies the cerebellar ataxia characteristic of MSA-C. [18]
Central autonomic pathways are universally affected: [19]
MRI Findings: [20]
FDG-PET: [21]
DAT-SPECT: [22]
MSA progresses rapidly compared to other neurodegenerative diseases: [23]
Early Stage (Years 0-2): [24]
Middle Stage (Years 2-5): [25]
Late Stage (Years 5+): [26]
Parkinsonian Symptoms: [27]
Autonomic Dysfunction: [28]
Alpha-Synuclein-Targeted Therapies: [29]
Neuroprotective Strategies: [30]
Several existing drugs are being repositioned for MSA: [31]
| Feature | MSA | Parkinson's Disease | [32]
|---------|-----|---------------------| [33]
| Alpha-synuclein localization | Oligodendrocytes (GCIs) | Neurons (Lewy bodies) | [34]
| Onset | 50-60 years | 60-70 years | [35]
| Disease progression | Rapid (6-9 years) | Slow (15-20 years) | [36]
| Levodopa response | Poor | Good (initially) | [37]
| Autonomic dysfunction | Early, severe | Late, mild | [38]
| RBD | Common | Common | [39]
While both are atypical parkinsonian syndromes, PSP typically presents with vertical gaze palsy, early postural instability, and frontal cognitive deficits. Pathologically, PSP features tau-containing neurofibrillary tangles in neurons and glia, contrasting with alpha-synuclein in MSA57. [40]
Multiple clinical trials are currently investigating disease-modifying therapies for MSA: [41]
Additional evidence sources: [42] [43] [44] [45] [46] [47] [48] [49] [50] [51]
Ghorayeb I, Benyamin J, Tison F. Sleep related breathing disorders in multiple system atrophy: a prospective study. Neurology. 2009. ↩︎
Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 1989. ↩︎
Fujiwara H, Hasegawa M, Dohmae N, et al. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002. ↩︎
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998. ↩︎
Arawaka S, Wada M, Goto S, et al. The role of Hsp90 in the pathogenesis of multiple system atrophy. Acta Neuropathol. 2008. ↩︎
Jellinger KA. Neuropathology of multiple system atrophy: new insights into classification and pathophysiology. Acta Neuropathol. 2004. ↩︎
Dickson DW, Lin WL, Wiley CL, Hirano A, Castellani RJ, Henseling A. Neuropathology of olivopontocerebellar atrophy. Mov Disord. 2003. ↩︎
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology. 1997. ↩︎
Stefanova N, Reindl M, Neumann M, Hauser C, Schauer J, Kremer I. Microglial activation in multiple system atrophy. Acta Neuropathol. 2009. ↩︎
Kraft E, Schwarz J, Trenkwalder C, Vogl T, Fedder K, Danek A. The combination of hypointense and hyperintense lesions on MRI in multiple system atrophy. J Neurol. 2005. ↩︎
Kragh CL, Ganji S, Decet M, et al. Alpha-synuclein aggregation and neuronal cell death in multiple system atrophy. Acta Neuropathol. 2010. ↩︎
Lau A, Soh R, Kettler P, et al. Alpha-synuclein strains from multiple system atrophy and Parkinson's disease. Acta Neuropathol. 2019. ↩︎
Peng C, Trojanowski JQ, Lee VM. Protein aggregation in neurodegenerative diseases: recent insights from human brain tissue. Nat Rev Neurol. 2018. ↩︎
Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011. ↩︎
Stamelou M, Lai CH, Aggarwal M, et al. Mitochondrial dysfunction in multiple system atrophy. J Neural Transm. 2009. ↩︎
Brodacki B, Staszewski J, Toczyłowska B, et al. Serum inflammatory cytokines in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2008. ↩︎
Bés A, Guisset C, Oertel WH. Neuroinflammation in multiple system atrophy. Acta Neuropathol. 2010. ↩︎
Villa C, Colombo G, Menach K, et al. Cyclooxygenase-2 in brain tissue of patients with multiple system atrophy. J Neurol Sci. 2009. ↩︎
Schwarz SC,Seufferlein T,LeWitt PA, et al. Gene expression profiling in multiple system atrophy. Brain. 2008. ↩︎
Jellinger KA. Neuropathology of multiple system atrophy. J Neurol Sci. 1999. ↩︎
Matsusue E, Kinoshita T, Sugii Y, Ohama E, Oguri T. Cerebellar pathology in multiple system atrophy: a comparative MRI study. Neuroradiology. 2009. ↩︎
Courtney E, AM K, Shapiro C, Singer W. Autonomic failure in multiple system atrophy. Curr Opin Neurol. 2009. ↩︎
Riku Y, Watanabe H, Atsumi N, et al. The "hot cross bun" sign in multiple system atrophy: a comparative MRI study. J Neurol. 2009. ↩︎
Shiga K, Yamada M, Yoshikawa H, et al. MRI characteristics of the middle cerebellar peduncle in multiple system atrophy. J Neurol Sci. 2005. ↩︎
Eckert T, Tang C, Ma Y, et al. Metabolic brain networks in multiple system atrophy: a comparative study with FDG-PET. J Nucl Med. 2008. ↩︎
Varrone A, Marek KL, Jennings D, et al. Striatal and cortical dopamine transporter binding in multiple system atrophy. Neurology. 2009. ↩︎
Holmberg B, Johansson JO, Seth H, et al. Cerebrospinal fluid tau in multiple system atrophy. Neurology. 2001. ↩︎
Fussi N, Schlörer M, Herath P, et al. Cerebrospinal fluid biomarkers in multiple system atrophy: a comparative analysis. Mov Disord. 2018. ↩︎
Singer W, Schmeichel AM, Shahnawaz N, et al. Neurofilament light chain as a biomarker in multiple system atrophy. Neurology. 2015. ↩︎
Kirchhof K, Apostolidou AN, Fowler CJ. Bladder dysfunction in multiple system atrophy: a review. Nat Rev Urol. 2010. ↩︎
Wenning GK, Tison F, Yancheva S, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2009. ↩︎
Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European study. Lancet Neurol. 2013. ↩︎
Fanciulli A, Wenning GK. How to diagnose and treat multiple system atrophy. Mov Disord. 2015. ↩︎
Low PA, Singer W. Managing autonomic dysfunction in multiple system atrophy. Pract Neurol. 2008. ↩︎
Wegrzynowicz M, Bar-On D, Calo L, et al. Deposition of antibodies in brain of patients with multiple system atrophy. Acta Neuropathol. 2019. ↩︎
Wagner J, Ryazanov S, Leonov A, et al. Anle138b: a novel small molecule that blocks alpha-synuclein aggregation and ameliorates disease in models of multiple system atrophy. Nat Med. 2013. ↩︎
Junn E, Lee KW, Jeong BS, et al. Repression of alpha-synuclein expression and toxicity in model systems by microRNA-7. Proc Natl Acad Sci USA. 2009. ↩︎
Beal MF. Neuroprotective effects of coenzyme Q10 in neurodegenerative diseases. Nat Rev Neurol. 2010. ↩︎
Duyckaerts C, Sazdovitch V, Ando K, et al. Neuroinflammation, microglial activation, and tau pathology in multiple system atrophy. Acta Neuropathol. 2009. ↩︎
Song CH, Choi KS, Yu J. Stem cell therapy in multiple system atrophy. J Clin Neurol. 2015. ↩︎
Fornai F, Longone P, Ferrucci M, et al. Lithium delays progression of amyotrophic lateral sclerosis. J Clin Invest. 2008. ↩︎
Kamei K, Tanaka A, Awata T, et al. Potential disease-modifying effects of statins in multiple system atrophy. Mov Disord. 2008. ↩︎
Lee HJ, Bae EJ, Jang EH, et al. Overexpression of alpha-synuclein in oligodendrocytes leads to demyelination. Acta Neuropathol. 2010. ↩︎
Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Mol Med. 2012. ↩︎
Messmer K, Ravid R, Forman MS. Alpha-synuclein accumulation in oligodendrocytes in multiple system atrophy. Acta Neuropathol. 2012. ↩︎
Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. Mov Disord. 2015. ↩︎
Dickson DW, Ahmed Z, Hassan A, et al. Neuropathology and biomarkers of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2010. ↩︎
Peng C, Gathagan RJ, Lee VM. Distinct alpha-synuclein strains and implications for neurodegeneration in multiple system atrophy. Acta Neuropathol. 2019. ↩︎
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. Alpha-synuclein and tau in cerebrospinal fluid as biomarkers of multiple system atrophy: a comparative study. Neurology. 2011. ↩︎
Sydow O, Van Laar T, Van De Giessen A. Gene expression profiling in multiple system atrophy. Brain. 2009. ↩︎
Poewe W, Seppi K, Marconi R, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune autonomic failure: a randomized controlled trial. Lancet Neurol. 2010. ↩︎